Back to top

crispr: Archive

Zacks Equity Research

Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy

Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.

VRTXNegative Net Change BLUEPositive Net Change EDITPositive Net Change CRSPNegative Net Change

Zacks Equity Research

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.

VRTXNegative Net Change BLUEPositive Net Change EDITPositive Net Change CRSPNegative Net Change

Andrew Rocco

5 Reasons to be Bullish into 2024

Stock Strategist Andrew Rocco unveils 5 bullish undercurrents that will push stocks even higher into the new year.

NVOPositive Net Change NVDANegative Net Change QQQNegative Net Change IWMPositive Net Change KRENegative Net Change CRSPNegative Net Change METANegative Net Change